

Astellas, Mirabegron PDUFA on 29th – Doubts Prevail Over Favorable Outcome!

https://marketpublishers.com/r/A70AF1FCC13EN.html

Date: June 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: A70AF1FCC13EN

Abstracts

We are skeptical if the FDA will approve Mirabegron (first in class ?3-AR agonist, overactive bladder syndrome, OAB) on approaching PDUFA date on June 29th. Despite the fact that CV risk concerns raised with Mirabegron are mild in nature and the FDA's Advisory Committee recommended that the risk/benefit profile of the drug is favorable (April 5th, in 7:4 ratio) - we think that FDA will not consider the factors discussed at advisory panel in isolation.

However, in case of timely approval, which seems to be more common view of street - we expect mirabegron to generate \$300m revenue by 2016 from USA; our WW peak sales estimates from mirabegron is \$550m.



Contents

COMPANIES MENTIONED

Astellas



I would like to order

Product name: Astellas, Mirabegron PDUFA on 29th – Doubts Prevail Over Favorable Outcome!

Product link: https://marketpublishers.com/r/A70AF1FCC13EN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A70AF1FCC13EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970